Symptom burden and treatment patterns in primary biliary cholangitis: A systematic review and meta-analysis Authors: Ambrose Hon-Lam Chung, Jarell Jie-Rae Tan, Roe Xin Jacqueline Yap, Jing Hong Loo, Wei Xuan Tay, Corrine Lee Singh, Shi Jie Ong, Aidan Yuan Jie Low, Yikun Lin, Ellina Lytvyak, Andrew Mason, Aldo J. Montano-Loza, Yu Jun Wong Published: 2026 ABSTRACT Background:Patients with primary biliary cholangitis (PBC) often suffer from debilitating symptoms, yet the overall symptom burden has not been systematically quantified. This study aims to systematically review the prevalence and severity of the symptom burden in PBC patients.Methods:We conducted a systematic search of 3 electronic databases to include studies that reported the prevalence and severity of PBC symptoms. Subgroup analyses were performed based on study type, publication year, risk of bias, study location, sex, and latitude.Results:A total of 25 studies involving 13,178 patients were included. Fatigue was the most common symptom, affecting 51% of patients, followed by pruritus at 33%. Severe fatigue and severe pruritus were reported in 23% and 10% of patients, respectively. The prevalence of fatigue was significantly higher in more recent studies, those with smaller sample sizes, and studies published as abstracts. Fatigue score was significantly higher in female patients compared with males. Severe fatigue was more prevalent in studies conducted in North America/Europe than those from Asia (26% vs. 8%, p=0.0005), and in studies with a higher proportion of patients with cirrhosis (28% vs. 8%, p=0.0005). Despite the high burden, only 36% of PBC patients with pruritus received anti-pruritic treatment, with antihistamines being the most frequently prescribed medication.Conclusions:Over half of PBC patients experience significant symptom burden, with substantial ethnic disparities identified. The proportion and quality of appropriate symptom management in PBC are suboptimal. There remains an unmet need for standardized assessment, consistent reporting, and improved management strategies for PBC-related symptoms in future research. INTRODUCTION Primary biliary cholangitis (PBC) is an autoimmune cholestatic liver disease characterized by granulomatous lymphocytic cholangitis. If left untreated, it can progress to cirrhosis, hepatocellular carcinoma, liver failure, and ultimately death.1–3 The prevalence of PBC has been rising over time, with the most rapid rise observed in the Western Pacific region. 4 Patients with PBC might suffer from both complications related to cirrhosis and debilitating symptoms such as fatigue and pruritus. Those who are symptomatic at diagnosis tend to have more advanced disease compared with asymptomatic patients. 5 Importantly, even in the absence of symptoms, PBC is associated with poorer survival compared with the general population.6,7 Symptom evaluation is a crucial aspect of managing patients with PBC, as symptoms can profoundly impair their quality of life and functional status. 8 The presence of pruritus, in particular, plays an important role in guiding second-line treatment decisions for patients who have an incomplete response to ursodeoxycholic acid (UDCA). 9 Moreover, the treatment landscape of PBC has evolved rapidly in recent years, providing more effective therapeutic options for symptom management.10,11 Still, several gaps remain in the management of symptoms in patients with PBC. Firstly, it was unclear to what extent the reported symptom burden may be influenced by the use of concurrent anti-pruritic and other PBC medications.12,13 In addition, whether the symptom burden varies by geographical region due to differences in ethnicity and access to medications has not been well established. With recent advances in the therapeutic options available for managing PBC-related symptoms, a timely systematic review of symptom prevalence, burden, and treatment approaches is warranted. To address these gaps, this meta-analysis aims to provide a comprehensive and up-to-date synthesis of the prevalence, symptom burden, and treatments used to manage the symptom burden in patients with PBC. METHODS Search strategy We conducted a comprehensive search of 3 electronic databases (PubMed, EMBASE, and Web of Science) from inception until May 24th, 2025. The search terms included a combination of “primary biliary cholangitis”, “primary biliary cirrhosis”, “biliary cirrhosis”, “pruritus”, “fatigue”, and “quality of life”, using both free text keywords and MeSH terms. The search strategy is provided in Supplementary Methods, http://links.lww.com/HC9/C297. This systematic review and meta-analysis were conducted in accordance with the Cochrane Handbook guidelines 14 and reported according to the Preferred Reporting Items for Systematic Reviews and Meta-analysis (PRISMA) guidelines (Supplemental Table S1, http://links.lww.com/HC9/C297). 15 The study protocol and pre-specified outcomes were prospectively registered in PROSPERO (CRD420251021983). Selection of studies After removing duplicate records, 8 co-authors (Ambrose Hon-Lam Chung, Jarell Jie-Rae Tan, Roe Xin Jacqueline Yap, Wei Xuan Tay, Corrine Lee Singh, Shi Jie Ong, Aidan Yuan Jie Low, and Yikun Lin) independently screened the titles and abstracts of the retrieved studies. Full texts were then reviewed to determine each study’s eligibility for inclusion. We included studies that met the following criteria: (1) cohort or cross-sectional design; (2) reported the prevalence or severity of common symptoms in patients with PBC. We excluded case reports, reviews, meta-analyses, editorials, protocols, and studies not conducted in humans. In cases where multiple studies reported overlapping data from the same cohort, only the largest and/or most updated study was included. All discrepancies were resolved through consensus with a senior author (Yu Jun Wong). Risk of bias assessment The risk of bias in each included study was independently assessed by 2 authors using the criteria developed by Hoy et al. 16 Studies were scored (0 or 1) based on 9 items, with scores of 7–9, 4–6, and 0–3 considered to have a low, moderate, and high risk of bias, respectively. Traffic light plots were generated using the RobVis tool to summarize the risk of bias in included studies. 17 Data extraction Using a standardized data collection form, we collected the following information from all eligible studies: (1) study characteristics, including first author, publication year, study type, and number of PBC patients; (2) population characteristics, such as mean age, prevalence of symptoms, and severity of symptoms; and (3) relevant clinical characteristics, such as the presence of cirrhosis. The geographical latitude of each study’s location was determined using Google Earth (v7.3, Google Inc., USA). 4 Outcomes assessed The primary outcomes evaluated in this study were: (1) the prevalence of common symptoms in patients with PBC; (2) the severity of these symptoms; and (3) treatment patterns in the management of PBC-related symptoms. Data analysis Before proceeding from systematic review to meta-analysis, we first summarized the characteristics of all included studies to assess their comparability for pooled analysis. Once a sufficient number of studies were available, we proceeded with the meta-analysis to improve the precision of our estimate. 18 For the prevalence of PBC symptoms, we applied the Freeman–Tukey double arcsine transformation to stabilize the variance of different studies. 19 Pooled prevalence estimates for each symptom were calculated using a random-effects model and presented with a 95% confidence interval (95% CI). Heterogeneity among studies was assessed using the Cochran Q test, while the extent of variability due to between-study heterogeneity was quantified using I 2 statistics. I 2 values of <25, 25–50, and >50% represented low, moderate, and high heterogeneity, respectively. 18 The percentage of variability due to between-study heterogeneity was assessed using the Egger test for continuous variables. 20 To explore the potential sources of heterogeneity, subgroup analyses were conducted based on publication type, publication year, presence of cirrhosis, and geographical latitude. In addition, we performed subgroup analysis restricted to studies employing validated PBC questionnaires to ensure the reliability of our estimates. Clinically significant symptoms were defined as moderate to severe symptoms according to the threshold reported by individual studies. Potential bias from dominant studies was assessed using the leave-one-out method, which involves the sequential exclusion of individual studies to evaluate their impact on the overall results. Funnel plots were visually inspected to detect any asymmetry in the distribution of data points across the vertical treatment effect axis, which may indicate publication bias. All statistical analyses were conducted using R version 4.0.5 (R Foundation for Statistical Computing, Vienna, Austria) using the “metap” package. 21 p-Value <0.05 was considered to be statistically significant. RESULTS Characteristics of included studies Our initial search across three electronic databases (PubMed, EMBASE, and Web of Science) identified 3877 citations. After removing 1593 duplicates, we screened 2284 records and ultimately included 25 studies encompassing a total of 13,178 patients with PBC. The study selection is summarized in the PRISMA flowchart (Figure 1), while the main characteristics of the included studies are detailed in Table 1 and Supplemental Table S4, http://links.lww.com/HC9/C297. Preferred Reporting Items for Systematic Reviews and Meta-analysis (PRISMA) flowchart. TABLE 1Baseline characteristics of study populationsNoAuthor, yearCountry/regionStudy designSample sizeSex ratio (F:M)Main evaluation toolSymptom prevalence (%) a Symptom severity b FatiguePruritusFatiguePruritus1Al-Harthy, 2010 22 CanadaR, SC32316:1PBC-4044%46% c 27 (11)4 (3)2Blackburn, 2007 23 UKR, SC24All femalePBC-4042%NA37 (8)5 (4)3Björnsson, 2009 24 Sweden, UK, USAP, MC20812:1FIS31%NA28 (12–47)NA4Carey, 2018 25 USAP, MC9411:1PBC-4066%32%29.05.05Cauch-Dudeck, 1998 26 CanadaP, SC886:1FAI68%NA5 (2)NA6de Veer, 2023 27 NetherlandsR, MC17813:1PBC-4073%25%3 (2–4)2 (1–3)7Goldblatt, 2002 28 UKR, MC13610:1FIS31%NA40 (0–138)NA8Gungabissoon et al., 2024 13 USAR, MC2259:1PBC-40NA53%NANA9Hergade, 2019 29 UKR, MC219410:1PBC-40 NRSNA28%NA4 (0–9)10Herta, 2023 30 GermanyR, MC4967:14-Point Likert ScaleNA32%NANA11Honig, 2018 31 GermanyR, MC57712:1NRS ItchyQoL82% c 33%NA412Jones, 2006 32 UKP, MC2811:1FIS71%NA41 (0–138)NA13Liu, 2021 33 ChinaR, SC3836:1PBC-40NANA24 (10)3 (2)14Martin, 2019 34 USA, CanadaR, MC209:1PBC-4085% c 100% c NA51 (25)15Mayo et al., 2023 12 USAP, MC21111:1PBC-40NA30%61.0516Medina-Morales, 2022 35 USAP, SC68NAPBC-40NA40%NA12 (8–18)17Mells et al., 2013 8 UKR, MC235310:1PBC-4045%38%NANA18Phaw, 2021 36 UKR, MC2002NAPBC-4060%NA30 (11)5 (4)19Poupon, 2004 37 FranceP, MC2767:1NHP32%20%NANA20Raszeja-Wyszomirska, 2016 38 PolandR, MC20511:1PBC-40NANA30 (11)6 (5)21Rice et al., 2021 39 UKR, MC222210:1PBC-4062% c 45% c NANA22Schattenberg, 2023 40 GermanyR, MC20NANRS PROMIS Fatigue-SFNA70%NANA23Wong, 2008 41 Hong KongR, SC4410:1SF-3664% c 64% c 2.9 (1.2)3 (1)24Yagi, 2018 42 JapanR, MC4968:1PBC-4046%28%NANA25Yassin, 2022 43 TurkeyR, SC3718:1PBC-4068%32%24 (10)4 (3) a Clinically significant symptoms (moderate/severe). b Reported in mean (standard deviation) or median (interquartile range) c Total prevalence of symptoms.Abbreviations: FAI, Fatigue Assessment Instrument; FIS, Fatigue Impact Scale; MC, multicenter; NA, not available; NHP, Nottingham Health Profile; OCA, obeticholic acid; P, prospective study; R, retrospective study; SC, single-center; SF-12, Short-Form 12; SF-36, Short-Form 36. Baseline characteristics of study populations Clinically significant symptoms (moderate/severe). Reported in mean (standard deviation) or median (interquartile range) Total prevalence of symptoms. Abbreviations: FAI, Fatigue Assessment Instrument; FIS, Fatigue Impact Scale; MC, multicenter; NA, not available; NHP, Nottingham Health Profile; OCA, obeticholic acid; P, prospective study; R, retrospective study; SC, single-center; SF-12, Short-Form 12; SF-36, Short-Form 36. Overall, 25% of patients had cirrhosis at the time of symptom evaluation (95% CI: 20%–32%, I 2=90%, 11 studies). The most commonly used symptom evaluation tool was the PBC-40 questionnaire, employed in 64% of the studies (16 out of 25). Only 4 studies reported on comorbidities associated with PBC symptoms, such as thyroid disease, Sjögren’s syndrome, or depression. Notably, no study evaluated the role of sarcopenia and muscle dysfunction in relation to fatigue in PBC. During symptom assessment, 16% of patients were reported to be using obeticholic acid (95% CI: 0.10–0.23, I 2=79%, 4 studies), while 10% were using fibrates (95% CI: 0.05–0.19, I 2=93%, 6 studies) (Supplemental Table S4, http://links.lww.com/HC9/C297). Most studies were multicentric (72%) and were geographically distributed primarily in Europe (60%, 15/25), followed by North America (28%, 7/25), then Asia (12%, 3/25). The traffic light plot indicated that the majority of included studies had a low risk of bias (Supplemental Figure S1, http://links.lww.com/HC9/C297). This meta-analysis was conducted and reported according to the PRISMA reporting guidelines (Supplemental Table S1, http://links.lww.com/HC9/C297). Prevalence of PBC symptoms Overall, nearly half of PBC patients reported clinically significant symptoms, with a pooled prevalence of 48% (95% CI: 41%–57%, I 2=99%, 23 studies). Fatigue was the most common symptom, affecting approximately half of the patients with PBC (51%, 95% CI: 42%–60%, I 2=96%, 13 studies) (Figure 2), followed by pruritus, which was reported in 33% of patients (95% CI: 28%–38%, I 2=91%, 13 studies) (Supplemental Figure S2, http://links.lww.com/HC9/C297). Sicca symptoms were reported in 16% of PBC patients (95% CI: 12%–22%, I 2=65%; 2 studies). The least common symptoms were jaundice (4%, 95% CI: 3%–5%, I 2=17%, 4 studies) and right upper quadrant pain (3%, 95% CI: 1%–5%, I 2=0%, 2 studies) (Supplemental Table S2, http://links.lww.com/HC9/C297). The pooled prevalence of clinically significant fatigue in patients with primary biliary cholangitis. Based on the PBC-40 questionnaire, nearly all patients reported experiencing PBC-related symptoms of varying severity (Supplemental Table S3, http://links.lww.com/HC9/C297). However, the proportion of patients who reported moderate to severe symptoms varied across domains, ranging from 34% for pruritus (95% CI: 28%–40%, I 2=94%, 8 studies) to 54% for fatigue (95% CI: 48%–61%, I 2=94%, 8 studies) (Supplemental Table S2, http://links.lww.com/HC9/C297). Fatigue Fatigue was the most commonly reported symptom, affecting approximately half of patients with PBC. The burden of fatigue was notably higher in more recent studies (2020 and onwards: 66% vs. before 2020: 46%, p<0.01) (Supplemental Figure S3, http://links.lww.com/HC9/C297), in studies with smaller sample sizes (66% vs. 45%, p=0.0009) (Supplemental Figure S4, http://links.lww.com/HC9/C297), and studies published as abstracts compared with full-text articles (66% vs. 50%, p=0.0224) (Supplemental Figure S5, http://links.lww.com/HC9/C297). In addition, the fatigue score was significantly higher in female patients compared with males (standard mean difference=0.37, 95% Cl: 0.19–0.55; p<0.0001, 4 studies) (Supplemental Figure S6, http://links.lww.com/HC9/C297). Overall, the pooled prevalence of severe fatigue was 23% (95% CI: 16%–30%, I 2=95%, 9 studies). The prevalence of clinically significant fatigue among patients with primary biliary cholangitis was significantly higher in studies conducted in North America/Europe than in studies conducted in East Asia/Middle East (26% vs. 8%, p=0.0017) (Figure 3), as well as in studies with a higher proportion of patients with cirrhosis (28% vs. 8%, p=0.0005) (Figure 4). The burden of clinically significant fatigue was not significantly associated with geographic latitude, risk of bias, and study location (Table 2). The pooled prevalence of severe fatigue among patients with primary biliary cholangitis was higher in studies conducted in North America/Europe than in studies conducted in East Asia/Middle East. The pooled prevalence of severe fatigue was higher among studies with a higher proportion of cirrhosis patients. A high proportion of cirrhosis was defined using the cut-offs of (A) 15% and (B) 25% of the individual study cohort size. TABLE 2Subgroup analysis on the pooled prevalence of clinically significant fatigue in patients with primary biliary cholangitisSubgroupsNumber of studiesNumber of patientsProportion I 2 p Fatigue Abstract19466% (55%–75%)NA 0.0224 Full text12614950% (41%–59%)96%Publication year <202010402646% (37%–56%)90% 0.0033 >20203221766% (57%–75%)84%Sample size <100527166% (60%–71%)35% 0.0009 >1008597245% (35%–55%)97%Latitude <455103857% (45%–68%)90%0.3147 >458520548% (35%–60%)97%Risk of bias Low11589653% (42%–63%)96%0.1442 Moderate234744% (39%–49%)0%Study location North America/Europe11571051% (41%–61%)96%0.8405 East Asia/Middle East253354% (29%–77%)89% Subgroup analysis on the pooled prevalence of clinically significant fatigue in patients with primary biliary cholangitis Pruritus Overall, 34% of patients with PBC reported clinically significant pruritus (95% CI: 28%–39%, I 2=91%, 12 studies). Among these, 10% experienced severe pruritus (95% CI: 4%–18%, I 2=94%, 5 studies), and 15% underwent liver transplantation for pruritus. 39 The burden of pruritus was not significantly associated with publication type, publication year, study design, geographic latitude, presence of cirrhosis, study location, or risk of bias (Table 3). In particular, the pooled pruritus scores from studies conducted in North America and Europe did not differ significantly from those reported in studies conducted in East Asia (Supplemental Figure S7, http://links.lww.com/HC9/C297). TABLE 3Subgroup analysis on the pooled prevalence of clinically significant pruritus in patients with primary biliary cholangitisSubgroupsNumber of studiesNumber of patientsProportion I 2 p Pruritus Abstract5125233% (28%–47%)69%0.3099 Full text8597032% (28%–39%)94%Publication year <20206598930% (25%–35%)93%0.1305 >20207123339% (29%–49%)89%Sample size <100421642% (27%–58%)71%0.2168 >1009700632% (26%–38%)93%Latitude <456113036% (28%–44%)89%0.1868 >457607430% (25%–35%)93%Risk of bias Low10395535% (28%–43%)91%0.2569 Moderate3326731% (28%–34%)62%Study location North America/Europe11668935% (28%–41%)96%0.1206 East Asia/Middle East253328% (25%–32%)89% Subgroup analysis on the pooled prevalence of clinically significant pruritus in patients with primary biliary cholangitis Treatment of pruritus Overall, 8 studies reported the use of anti-pruritic medication at the time of symptom assessment. Among patients with pruritus, only 36% received anti-pruritic treatment (95% Cl: 19%–59%, I 2=99.2%, 7 studies) (Supplemental Figure S8, http://links.lww.com/HC9/C297). Antihistamines were the most frequently prescribed medication, used in 22% of patients (95% CI: 10%–50%, I 2=95%, 4 studies), followed by bile acid-binding resins (17%), sertraline (7%), rifampicin (6%), opiate antagonists and fibrates (4%) (Supplemental Table S4, http://links.lww.com/HC9/C297). Sensitivity analysis Sequential exclusion of individual studies did not significantly change the pooled prevalence estimates for fatigue or pruritus (Supplemental Figures S9, S10, http://links.lww.com/HC9/C297). Similarly, when analyses were restricted to studies using validated questionnaires for symptom assessment, the pooled prevalence of clinically significant fatigue and pruritus remained consistent (Supplemental Figures S11, S12, http://links.lww.com/HC9/C297). Both the Egger test and visual inspection of the funnel plot indicated no evidence of publication bias (Supplemental Figure S13, http://links.lww.com/HC9/C297). DISCUSSION Patients with PBC suffer from debilitating symptoms, yet accurately quantifying the disease burden and clinical impact of these symptoms remains challenging. This meta-analysis, which included 13,178 patients from 25 studies, revealed that nearly 1 in every 2 PBC patients experienced clinically significant symptoms using standardized symptom assessment tools. Notably, ~1 in 4 patients with PBC reported severe fatigue or pruritus. Interestingly, the prevalence of severe fatigue was significantly higher in studies conducted in North America/Europe than in studies conducted in Asia. To our best knowledge, this disparity has not been previously documented and merits further investigation. Our systematic review and meta-analysis confirmed that fatigue and pruritus are the 2 most commonly reported symptoms in patients with PBC, with a pooled prevalence of 52% and 33%, respectively. Although many patients are asymptomatic at diagnosis, up to 71% may develop symptoms during follow-up. 5 Current clinical guidelines recommend regular symptom evaluation and management in patients with PBC.1,2 However, real-world studies have identified significant gaps in symptom management. For example, data from both the UK nationwide audit and the TARGET-PBC cohorts revealed that more than one-third of patients had not been assessed for fatigue or pruritus within the previous 2 years.12,44 This gap partly reflects a discordance between physicians’ and patients’ perceptions regarding the impact of symptoms in PBC. 13 Given that accurate symptom evaluation is a critical first step toward improving quality of life, we recommend using the PBC-40 questionnaires at the point of diagnosis. This tool was specifically developed for patients with PBC, has been well-validated across different patient populations, and is incorporated into clinical trials to assess therapeutic efficacy.45–47 Despite being the most common symptom reported among patients with PBC, fatigue assessment remains subjective and challenging to manage. Future research should focus on determining the optimal frequency for fatigue assessment to maximize patient benefit without imposing additional burden on those affected by this debilitating symptom. Currently, there is no approved pharmacological treatment specifically for fatigue, which may persist even after liver transplantation. 48 The latest guidelines from the European Association for the Study of the Liver (EASL) recommend addressing contributing factors such as nocturnal pruritus and encouraging patients to avoid social isolation. 2 Notably, a recent clinical trial (EXCITED) demonstrated that a 12-week structured home-based exercise program can significantly improve fatigue in patients with PBC. 49 Although fatigue-related comorbidities, including anemia, autonomic dysfunction, hypothyroidism, vitamin D deficiency, sarcopenia, and depression, have been studied individually, further research is needed to determine the extent to which their targeted management contributes to fatigue reduction in PBC populations. 29 Despite the significant impact of pruritus on quality of life, half of the patients with PBC experiencing clinically significant pruritus remained untreated.39,44 Moreover, inappropriate medical management of cholestatic pruritus is common in this population. Antihistamines were the most frequently prescribed treatment for cholestatic pruritus, highlighting an important knowledge gap in managing cholestatic pruritus. Because cholestatic pruritus is not histamine-driven, antihistamines are generally ineffective in relieving this symptom. In fact, their use may exacerbate other PBC-related symptoms such as fatigue and dry mouth. 30 Recent trials showed promising results with ileal bile acid transporter (IBAT) inhibitors in treating pruritus associated with PBC. 10 These agents may offer a valuable treatment option for patients suffering from debilitating pruritus, particularly in those without advanced liver disease. Given these findings, it is important to raise physicians’ awareness of effective treatment modalities and to prioritize systematic symptom assessment in patients with PBC. Accurate and timely evaluation of symptoms like pruritus and fatigue is the key to improving patients’ quality of life. To the best of our knowledge, this current meta-analysis is the first to systematically summarize the symptom burden experienced by patients with PBC. We only included studies that utilized dedicated instruments specifically designed for symptom assessments. Importantly, the pooled prevalence of symptom burden showed consistent results, both in sensitivity analyses restricted to studies with validated assessment tools and across various subgroup analyses. We believe these robust estimates will serve as valuable references and assist in sample size calculations for the design of future therapeutic trials in PBC. We acknowledge several limitations in this study. Firstly, despite conducting multiple subgroup analyses, heterogeneity remained high for certain subgroups. The substantial heterogeneity observed in our pooled estimates is likely related to the lack of standardized symptom evaluation tools and the limited reporting of both comorbidities and treatment use. First, to comprehensively summarize the existing literature, we employed a range of symptom assessment tools. While the PBC-40 is a well-validated and disease-specific instrument for evaluating symptom burden in PBC, several studies used alternative measures targeting individual symptoms [eg, Short-form 36 (SF-36), Fatigue Impact Scale (FIS), and Fatigue Severity Scale]. Variations in sensitivity, specificity, and symptom domains captured by these tools may have contributed to the variability across studies. That said, when subgroup analysis was performed based on validated tools, the prevalence of symptom burden remained unchanged. Second, the presence of comorbidities, such as thyroid disorders, depression, and other autoimmune diseases, can mimic or worsen PBC symptoms. Reporting of these comorbidities was inconsistent (as shown in Supplemental Table S4, http://links.lww.com/HC9/C297), introducing additional heterogeneity that may affect the comparability of symptom assessments. Third, the use of second-line therapies (obeticholic acid or fibrates), which may influence symptom severity, was infrequently reported in the included studies. Future studies would benefit from adopting standardized symptom assessment tools and comprehensive reporting of comorbidities and treatment regimens. Hence, the development of an international consensus statement on symptom evaluation in PBC could further promote uniformity, enhance comparability across studies, and strengthen confidence in pooled symptom burden estimates. In addition, the absence of individual patient data limited our ability to explore the downstream impact of specific symptoms, such as pruritus and sleep disturbances. Given the limited number of studies and variability in how pruritus management was reported, the observed treatment rates should be interpreted with caution. Future research with more standardized and systematic documentation of pruritus assessment and therapeutic interventions is needed to provide more robust and generalizable estimates. Finally, our analyses did not address the dynamic changes in symptom burden over time, particularly in relation to treatment such as obeticholic acid, fibrates, or treatment specifically targeting pruritus. These important aspects should be addressed in future studies. In conclusion, nearly half of the patients with PBC experienced clinically significant symptoms, particularly pruritus and fatigue, which substantially impair their quality of life. It is crucial to increase physician awareness of the importance of assessing and managing the symptom burden to better alleviate the symptom burden in patients with PBC. Supplementary Material